Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services

Beijing, China – March 22, 2022 — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.

Image credit: Sino Biological

Under the terms of this partnership, Sino Biological will add Ainnocence’s cutting-edge artificial intelligence-based prediction technology to its current antibody development CRO services offering. The AI-based platform enables fast, efficient, and accurate prediction of antibody-antigen interaction, including binding affinity assessment. This empowers Ainnocence, using computer-based algorithms, to accurately design antibodies to be developed and manufactured by Sino Biological for clients worldwide.  Financial terms were not disclosed.

Dr. Rob Burgess, Sino Biological’s Chief Business Officer, stated “The addition of Ainnocence’s AI-based antibody-antigen binding prediction technology will enable Sino Biological to further enhance its antibody development CRO services offering, thus saving customers precious development time and ensuring antibody-antigen binding affinities that meet their strict demands. We look forward to working with the Ainnocence team to offer next-generation antibody design and development services.”

“I’m confident that our partnership with Sino Biological will catalyze Ainnocence’s Biologics AI design applications in the biotech industry, and ultimately accelerate clinical translation of cutting-edge medical technologies.” stated Dr. Lurong Pan, Ainnocence CEO.

About Sino Biological:

Sino Biological, Inc.

Video credit: Sino Biological

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.

About Ainnocence

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company’s third-generation AI system delivers lightening-fast virtual screening and multi-objective pharmacological profile optimization for small molecule, antibody and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a short list of candidates with very high wet lab hit rate, and a dramatically reduced discovery time and cost.

Contact Us:

Sino Biological, Inc.

[email protected]

www.sinobiological.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2022, March 24). Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services. News-Medical. Retrieved on August 08, 2022 from https://www.news-medical.net/news/20220324/Sino-Biological-and-Ainnocence-Partner-to-Offer-Next-Generation-Antibody-Development-CRO-Services.aspx.

  • MLA

    Sino Biological Inc.. "Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services". News-Medical. 08 August 2022. <https://www.news-medical.net/news/20220324/Sino-Biological-and-Ainnocence-Partner-to-Offer-Next-Generation-Antibody-Development-CRO-Services.aspx>.

  • Chicago

    Sino Biological Inc.. "Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services". News-Medical. https://www.news-medical.net/news/20220324/Sino-Biological-and-Ainnocence-Partner-to-Offer-Next-Generation-Antibody-Development-CRO-Services.aspx. (accessed August 08, 2022).

  • Harvard

    Sino Biological Inc.. 2022. Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services. News-Medical, viewed 08 August 2022, https://www.news-medical.net/news/20220324/Sino-Biological-and-Ainnocence-Partner-to-Offer-Next-Generation-Antibody-Development-CRO-Services.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources